Carlos Alberto Alayo Lizana
Research Subjects
Carlos Alberto Alayo Lizana has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Gracia Del Carmen Polo Lecca
Servicio de Cardiología Clínica, Instituto Nacional Cardiovascular INCOR. Lima, Perú
1 shared publication - José María Carrasco Rueda
Servicio de Cardiología Clínica. Instituto Nacional Cardiovascular INCOR. Lima, Perú
1 shared publication - Juan Manuel Muñoz Moreno
Department of Internal Medicine, Macon and Joan Brock Virginia Health Sciences at Old Dominion University, Norfolk, VA 23507, USA
1 shared publication Luis Murillo Pérez
1 shared publication- Manuel Chacón-Diaz
Servicio de Cardiología, Clínica Delgado-Auna, Lima, Peru
1 shared publication - Ofelia Araoz Tarco
Instituto Nacional Cardiovascular (INCOR), EsSalud. Lima, Perú
1 shared publication
Latest Publications
- Open Access
- 15 December 2020
- Published by Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
- Vol. 1 (4) , 206-214
Características actuales y factores de riesgo de mortalidad en choque cardiogénico por infarto de miocardio en un hospital latinoamericano
Objective. To know the clinical characteristics and determine the related factors to higher in-hospital mortality in patients with cardiogenic shock (CS) due to myocardial infarction in a Peruvian reference hospital. Materials and methods. We conducted a prospective single-center cohort study, to evaluate the clinical characteristics, treatment, and complications of patients with CS due to myocardial infarction from March 2019 to August 2020 at the Instituto Nacional Cardiovascular INCOR. Factors related to higher in-hospital mortality and during follow-up were evaluated. Also, the IABP shock II score was applied to stratify the cohort. Results. Forty patients were included in the study, 75% of cases were due to left ventricular dysfunction, most of the men and with a median age of 75 (69-82) years. Fifty percent of cases presented CS after admission to the emergency room. Patients stratified by the IABP shock II score as low, intermediate, and high risk, had in-hospital mortality of 37.5%, 71.4%, and 91.6% respectively. In a hospital, mortality was 70%, higher in women, in those over 75 years old, and in those who developed CS during their hospitalization. Serum lactate > 4 mmol/L in univariate analysis was associated with higher mortality risk (HR: 2.8; IC:1.6-3.6, p=0.009). Survival to the end of the study was 12.8%. Conclusions. CS due to myocardial infarction is a clinical entity with high mortality in spite of revascularization and the available treatment in our reality. The highest mortality predictor was the serum lactate at admission >4 mmol/L. The IABP shock II score showed to be an accurate parameter to stratify the death risk in our population.
- 15 December 2020
- Published by Instituto Nacional Cardovascular - Carlos Alberto Peschiera Carrillo in Archivos Peruanos de Cardiología y Cirugía Cardiovascular
- Vol. 1 (4) , 206-214
Open AccessCaracterísticas actuales y factores de riesgo de mortalidad en choque cardiogénico por infarto de miocardio en un hospital latinoamericano
Objective. To know the clinical characteristics and determine the related factors to higher in-hospital mortality in patients with cardiogenic shock (CS) due to myocardial infarction in a Peruvian reference hospital. Materials and methods. We conducted a prospective single-center cohort study, to evaluate the clinical characteristics, treatment, and complications of patients with CS due to myocardial infarction from March 2019 to August 2020 at the Instituto Nacional Cardiovascular INCOR. Factors related to higher in-hospital mortality and during follow-up were evaluated. Also, the IABP shock II score was applied to stratify the cohort. Results. Forty patients were included in the study, 75% of cases were due to left ventricular dysfunction, most of the men and with a median age of 75 (69-82) years. Fifty percent of cases presented CS after admission to the emergency room. Patients stratified by the IABP shock II score as low, intermediate, and high risk, had in-hospital mortality of 37.5%, 71.4%, and 91.6% respectively. In a hospital, mortality was 70%, higher in women, in those over 75 years old, and in those who developed CS during their hospitalization. Serum lactate > 4 mmol/L in univariate analysis was associated with higher mortality risk (HR: 2.8; IC:1.6-3.6, p=0.009). Survival to the end of the study was 12.8%. Conclusions. CS due to myocardial infarction is a clinical entity with high mortality in spite of revascularization and the available treatment in our reality. The highest mortality predictor was the serum lactate at admission >4 mmol/L. The IABP shock II score showed to be an accurate parameter to stratify the death risk in our population.
- Open Access
- Vol. 1 (4) , 229-239
Controversias en Cardiología. Parte 2. ¿Debo tratar un síndrome coronario crónico de alto riesgo invasivamente desde el inicio? No, en la mayoría de casos
La definición de síndrome coronario crónico de alto riesgo varía según la prueba no invasiva empleada para evidenciar isquemia, lo que se consigue a través de un aumento del trabajo miocárdico y la demanda de oxígeno, generados con el uso de fármacos o el ejercicio. El abordaje inicial nos sumerge en la discusión de contextualizar en qué casos priorizar la terapia médica óptima inicial, frente al manejo invasivo inicial, con el objetivo de lograr la revascularización miocárdica. Este aspecto central será desarrollado en esta revisión, tomando en cuenta diversos estudios realizados hasta la fecha, en los que el manejo invasivo inicial no ha demostrado ser superior a la terapia médica óptima inicial en resultados clínicos relevantes como muerte o eventos adversos cardiovasculares mayores.
- Vol. 1 (4) , 229-239
Open AccessControversias en Cardiología. Parte 2. ¿Debo tratar un síndrome coronario crónico de alto riesgo invasivamente desde el inicio? No, en la mayoría de casos
La definición de síndrome coronario crónico de alto riesgo varía según la prueba no invasiva empleada para evidenciar isquemia, lo que se consigue a través de un aumento del trabajo miocárdico y la demanda de oxígeno, generados con el uso de fármacos o el ejercicio. El abordaje inicial nos sumerge en la discusión de contextualizar en qué casos priorizar la terapia médica óptima inicial, frente al manejo invasivo inicial, con el objetivo de lograr la revascularización miocárdica. Este aspecto central será desarrollado en esta revisión, tomando en cuenta diversos estudios realizados hasta la fecha, en los que el manejo invasivo inicial no ha demostrado ser superior a la terapia médica óptima inicial en resultados clínicos relevantes como muerte o eventos adversos cardiovasculares mayores.